Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

January 1, 2026

Study Completion Date

June 1, 2026

Conditions
Posttraumatic Stress Disorder
Interventions
DRUG

Prazosin

This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.

DRUG

Placebo

This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.

Trial Locations (1)

98108-1532

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

All Listed Sponsors
lead

VA Office of Research and Development

FED